Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension
This study has been completed.
Information provided by:
First received: September 9, 2005
Last updated: November 9, 2007
Last verified: November 2007
This study is to evaluate the end of treatment effect of Daglutril compared to placebo on top of losartan.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Placebo Controlled, Two-Treatment and Two-Period Cross-Over, Mono-Center Study to Evaluate the Efficacy and Safety of Daglutril 300 mg Once Daily Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Solvay Pharmaceuticals:
Contacts and Locations